Only in Titles

           Search results for: Breast cancer tissue array, 102 cases 102 cores   

paperclip

#19390427   2010/01/18 Save this To Up

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Over 80% of breast cancers in women with germline BRCA1 mutations are estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative ("triple negative") and most of these have a basal-like phenotype by expression profiling and immunophenotypic analysis. However, whether or not expression of biomarkers characteristic of basal-like breast cancers helps to define a subset of women with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an unresolved issue.

2236 related Products with: Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

IGF-1R Signaling Phospho- Epidermal Growth Factor ( Epidermal Growth Factor ( Epidermal Growth Factor ( Epidermal Growth Factor ( Human Insulin-like Growth Human Epidermal Growth Fa Human Insulin-like Growth Mouse Insulin-like Growth Mouse Epidermal Growth Fa Rat Insulin-like Growth F Growth Factor (Human) Ant

Related Pathways

paperclip

#17090184   2006/11/08 Save this To Up

Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.

Correct assessment of human epidermal growth factor receptor 2 (HER2) status is essential in managing patients with invasive breast carcinoma, but few data are available on the accuracy of laboratories performing HER2 testing by immunohistochemistry (IHC).

1994 related Products with: Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.

Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue micr FDA Standard Frozen Tissu FDA Standard Frozen Tissu Ofloxacin CAS Number [824 Multiple organ cancer tis Multiple organ tumor tiss ER Immunohistochemistry c HER2 (Phospho Tyr877) Ant HER2(Phospho Tyr1221 Tyr1 HER2 (Phospho Tyr1248) An

Related Pathways

paperclip

#15842048   2005/04/21 Save this To Up

Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?

We compared chromogenic in situ hybridization (CISH) with fluorescence in situ hybridization (FISH) for assessing HER-2/neu gene amplification using tissue microarrays (TMAs) made from formalin-fixed, paraffin-embedded tissue blocks from 113 cases of invasive breast carcinoma. TMAs were created using 0.6-mm tissue cores with 4 sampled cores per tumor. For both assays, a HER-2/chromosome 17 signal ratio of 2.0 or more was considered positive for gene amplification. The average ratio of cores from the same tumor was used for determination of gene amplification status of that particular tumor Of 113 cases, 102 were tested successfully by both assays. The results were concordant in 100.0% of cases (63 amplified; 39 nonamplified). All 22 cases of borderline (ratio, 2.0-2.5) or low-level (ratio, 2.6-3.9) amplification by FISH also showed HER-2 gene amplification by CISH. CISH is as sensitive as FISH in detecting borderline and low-level HER-2 amplification. Reliable recognition of the invasive carcinoma area by light microscopy and preservation of the test slides are added advantages of CISH. CISH performs as well as FISH in the analysis of HER-2 gene amplification in breast cancer and might have advantages in certain situations.

1623 related Products with: Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?

Breast cancer and matched Breast cancer and matched Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra

Related Pathways